The $400M financing removes near-term funding risk and provides capital to launch bota-vec and AAV-hAQP1 if approved. The non-dilutive structure preserves equity value while the equity component adds modest dilution (~2.4M shares at $10.52). Watch for Phase 2 AQUAx2 data readout in 2027 as a catalyst for the next $50M tranche. The capped royalty structure limits long-term revenue drag. The termination of Perceptive debt removes restrictive covenants.
Price Chart
Executive Summary
MeiraGTx entered into a $400M strategic financing with Oberland Capital, including up to $375M in non-dilutive royalty notes and $25M in equity. The initial $125M ($100M royalty notes + $10M equity) funds immediately, with additional tranches tied to clinical and regulatory milestones for AAV-hAQP1 and bota-vec. The deal replaces existing Perceptive debt and provides substantial capital to support commercialization of three late-stage gene therapy programs.
Key Financial Metrics
Key Facts
- Oberland Capital commits up to $375M in royalty notes and $25M in equity, totaling $400M
- Initial $100M royalty note funded June 30, 2026; $25M second purchase on July 17, 2026
- Revenue payments equal 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1, and bota-vec, capped at multiples of funded amount
- Additional $50M available upon positive Phase 2 AQUAx2 data for AAV-hAQP1
- Additional $50M available upon bota-vec regulatory approval; $50M upon AAV-hAQP1 approval
- Up to $100M available at mutual agreement for new products or business development
- Equity component: $10M initial at $10.52/share (950,570 shares) plus right to purchase up to $15M additional shares
- Existing Perceptive NPA (debt) redeemed in full and terminated
- Test Date for revenue payment cap adjustment is December 31, 2031
- Company may voluntarily repurchase notes in $25M increments at any time
Financial Impact
Up to $400M total capital commitment; $125M immediate ($100M royalty + $10M equity + $15M equity right); low single-digit capped royalties on three products
Risk Factors
- Royalty payments reduce future product revenue; cap may be reached quickly if products are highly successful
- Equity dilution from the $25M equity component and potential additional issuances
- Clinical and regulatory risks for AAV-hAQP1, bota-vec, and AAV-AIPL1
- Change of control provisions could require early repayment at capped multiples
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080949 |
| Document: mgtx-20260630xex10d2.htm | 0001104659-26-080949 |
| Document: mgtx-20260630xex10d3.htm | 0001104659-26-080949 |
| Document: mgtx-20260630x8k.htm | 0001104659-26-080949 |
| Document: mgtx-20260630xex99d1.htm | 0001104659-26-080949 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 144 | $10.82 | awaiting T+60 | — | $9.40 (−13.12%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.40 (−13.84%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.40 (−20.00%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.40 (−37.21%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.40 (−35.88%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.40 (−1.88%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers